Alnylam Pharmaceuticals ALNY ONPATTRO — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's onpattro — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's ONPATTRO — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported ONPATTRO — total revenues of $18.46M in Q2 2026.
- How has Alnylam Pharmaceuticals's ONPATTRO — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's ONPATTRO — total revenues decreased by 64.9% year-over-year, from $52.54M to $18.46M.
- What is the long-term trend for Alnylam Pharmaceuticals's ONPATTRO — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's ONPATTRO — total revenues has grown at a -22.3% compound annual growth rate (CAGR), from $474.74M to $172.79M.
- What does ONPATTRO — total revenues mean?
- Represents the total gross revenue generated from the sale of a specific therapeutic product within a defined reporting period. This metric reflects the market adoption and commercial performance of the drug before accounting for any sales deductions or rebates. It serves as a primary indicator of the product's contribution to the company's overall top-line growth.